ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2017) 50 P405 | DOI: 10.1530/endoabs.50.P405

Metoprolol succinate is associated with better quality of life in treatment of grave's disease

Hossam Ghazi

Mansoura Faculty of Medicine, Mansoura, Egypt.

Background: Grave’s Disease (GD) is the most common cause of hyperthyroidism and its effect of health status is well known. Beta blockers (BB) are routinely used to control thyrotoxic symptoms in initial phase of treatment of GD.

Objective: To study the effect of BB on quality of life (QOL) in patients with GD using different BB; propranolol, nebivolol and metoprolol succinate.

Method: A cohort prospective study was conducted on 109 patients with GD (63 females and 46 males in the period between August 2016 till April 2017). Patients were divided into three subgroups; group A (41 patients receiving carbimazole and propranolol 20–80 mg/day), group B (33 patients receiving carbimazole and nebivolol 2.5 mg/day) and group C (35 patients receiving carbimazole and metoprolol succinate 25–50 mg/day). All patients were examined, had thyroid profile and 36-item short form survey) SF-36) questionnaire to assess QOL as a baseline and 1 month later after treatment.

Result: There was no significant statistical difference regarding thyroid profile before and after treatment (P value >0.05), however group C had shown better results on SF-36 questionnaire score than the other subgroups (P value <0.05).

Conclusion: Metoprolol succinate is the best BB for control of thyrotoxic symptoms as it is associated with better QOL than other BB.

Article tools

My recent searches

No recent searches.